Zhonghua Nei Ke Za Zhi. 2018 Apr 1;57(4):242-251. doi: 10.3760/cma.j.issn.0578-1426.2018.04.004.
To develop a new evidence-based diagnosis, treatment guideline for rheumatoid arthritis (RA) in China.A multidisciplinary guideline development group was established. The grading of recommendations assessment, development and evaluation (GRADE) system was used to rate the quality of evidence and the strength of recommendations. Recommendations were derived from evidence body, the balance of benefits and harmsand patient's values and preferences.The guideline development group developed 10 recommendations for the diagnosis and treatment of RA. The guideline covered the classification criteria, disease activity monitoring and assessing, antirheumatic drugs (DMARDs) and glucocorticoids with treat-to-target approach of RA.This rheumatoid arthritis guideline was intended to serve as a tool for clinicians and patients for best decisions-making in China.
制定一部新的基于证据的中国类风湿关节炎（RA）诊断与治疗指南。成立了一个多学科指南制定小组。采用推荐意见分级评估、制定与评价（GRADE）系统对证据质量和推荐强度进行评级。推荐意见源自证据体、利弊权衡以及患者的价值观和偏好。该指南制定小组制定了10条关于RA诊断与治疗的推荐意见。该指南涵盖了RA的分类标准、疾病活动监测与评估、抗风湿药物（DMARDs）以及糖皮质激素的达标治疗方法。这部类风湿关节炎指南旨在为中国的临床医生和患者提供最佳决策工具。
